Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Voyageur Pharmaceuticals ( (TSE:VM) ) has issued an update.
Voyageur Pharmaceuticals has launched a U.S.-based iodine feasibility study to create a fully integrated North American manufacturing platform for iodine-based contrast media drugs. This initiative is part of their strategy to secure the radiology contrast media supply chain, reduce foreign dependency, and capture market share by providing a domestic, cost-efficient solution. The project includes bench-scale testing, potential facility construction, and aims to meet the increasing global demand for iodinated contrast media.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the production of iodine and barium-based contrast media drugs used in diagnostic imaging. The company aims to establish a fully integrated manufacturing platform in North America, addressing supply chain security concerns and reducing reliance on foreign manufacturers.
YTD Price Performance: 94.44%
Average Trading Volume: 210,576
Technical Sentiment Signal: Buy
Current Market Cap: C$29.45M
See more insights into VM stock on TipRanks’ Stock Analysis page.